"In a rare disease situation, you don't have time to wait 10 to 15 years... Let's make sure the drug is safe, but then let the doctors and the patients have more skin in the game."

Senator Marshall advocated for sweeping structural changes within the Food and Drug Administration (FDA) to prioritize treatments for patients battling rare and life-threatening conditions.